Nevro Corp. announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting held from January 12-15, 2023.

A total of 18 scientific abstracts reviewing clinical results for 10 kHz Therapy™, including two late-breaking presentations, seven podium presentations, and nine posters, will be presented at NANS 2023. This year, Nevro will showcase its comprehensive HFX™ spinal cord stimulation (SCS) portfolio, including its new AI-enabled HFX iQ™ system and support services for the treatment of chronic back and leg pain, including non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN) at exhibit booth #824. Painful Diabetic Neuropathy (PDN): Nevro's PDN data presentation ("10 kHz SCS Provides Durable Pain Relief for Patients with Painful Diabetic Neuropathy") will highlight complete 24-month follow-up results for pain relief and improved neurological function.

Nevro's SENZA-PDN trial is the largest, Level 1 randomized controlled trial (RCT) of spinal cord stimulation (SCS) treatment studying PDN completed thus far with 216 randomized subjects. Non-Surgical Back Pain (NSBP): Nevro's NSBP data presentation ("Treating Non-surgical Refractory Back Pain with 10kHz Spinal Cord Stimulation: 24 Month Follow-up from RCT") will feature 24-month outcomes from its SENZA-NSRBP RCT investigating 10 kHz Therapy for treating non-surgical refractory back pain, with 159 randomized participants from 15 study centers. A second NSBP data presentation ("10kHz Spinal Cord Stimulation for Non-Surgical Refractory Back Pain: Objective Functional Outcome to 24-Months") will feature the important improvements in non-pain outcomes such as sleep, mental health and function experienced by patients treated with 10 kHz Therapy in the SENZA-NSRBP RCT.

10-Year Real-World Data on Efficacy of 10 kHz Therapy: In addition to the data presentations described above, a poster presentation ("Ten-Year Real-World Data on the Efficacy of High-Frequency 10 kHz Spinal Cord Stimulation") will feature 10-year follow-up data from patients who originally participated in the SENZA EU study and continued with usual care in a real-world setting over a mean period of 10 years.